Stepan Company (SCL) Q4 2025 Earnings Call Transcript

Q4 2025 Earnings Call February 23, 2026 9:00 AM ESTCompany ParticipantsRuben Velasquez - VP & Chief Financial OfficerLuis Rojo ...

Stepan Reports Fourth Quarter and Full Year 2025 Results

Fourth Quarter 2025 Highlights. Reported net income was $5.0 million, up 49% versus the prior year. Adjusted net income (1) was a $ ...

Stepan outlines $100M cost savings plan and expects EBITDA growth in 2026 amid restructuring

CFO Ruben Velasquez stated, “Fourth quarter 2025 adjusted net loss was $0.5 million or down $0.02 per diluted share. Reported net income was $5 million, up 49% versus prior year, primarily reflecting ...

Stepan Q4 Earnings Call Highlights

Stepan (NYSE:SCL) executives used the company’s fourth-quarter and full-year 2025 earnings call to outline a year of portfolio actions, cost discipline, and improving cash generation, while also ...
AHA/ASA Journals

HEV-Targeted Antibody-Drug Conjugate Promotes Long-Term Cardiac Allograft Acceptance

BACKGROUND: The entrance of naive T cells into lymph nodes (LNs) is a crucial step for induction of heart transplant acceptance under costimulatory blockade. Specialized blood vessels within the LN ...